Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study

被引：23
|
作者：
Yasuhiko Iino
Matsuhiko Hayashi
Tetsuya Kawamura
Tatsuo Shiigai
Yasuhiko Tomino
Kenichi Yamada
Takeyuki Kitajima
Terukuni Ideura
Akio Koyama
Tetsuzo Sugisaki
Hiromichi Suzuki
Satoshi Umemura
Yoshindo Kawaguchi
Shunya Uchida
Michio Kuwahara
Tsutomu Yamazaki
机构：
[1] Nippon Medical School,Second Department of Medicine
[2] Keio University Hospital,undefined
[3] Jikei University School of Medicine,undefined
[4] Toride Kyodo General Hospital,undefined
[5] Juntendo University School of Medicine,undefined
[6] Sakura National Hospital,undefined
[7] Showa University Fujigaoka Hospital,undefined
[8] University of Tsukuba,undefined
[9] Showa University School of Medicine,undefined
[10] Saitama Medical School,undefined
[11] Yokohama City University School of Medicine,undefined
[12] Teikyo University Hospital,undefined
[13] Tokyo Medical and Dental University,undefined
[14] University of Tokyo,undefined
[15] Coordinating Committee,undefined
[16] Independent Data-Monitoring Committee,undefined
来源：
Journal of Clinical and Experimental Nephrology | 2003年 / 7卷 / 3期
关键词：
Losartan; Amlodipine; Proteinuria; Kidney; Creatinine; Angiotensin; Hypertension;
D O I：
10.1007/s10157-003-0241-3
中图分类号：
学科分类号：
摘要：
Background. Insufficiency of renal function and high blood pressure influence each other and eventually result in life-threatening endstage renal disease. It has been proposed that proteinuria per se is a determinant of the progression of chronic kidney disease (CKD). The therapeutic strategy for patients with proteinuric CKD and hypertension should therefore be targeted with a view not merely toward blood pressure reduction but also toward renoprotection.
引用
收藏
页码：221 / 230
页数：9
相关论文
共 23 条
123